People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $882.9M | 2021 |
| Halda Therapeutics, LLC | — | Pharma | Series D+ | $197.9M | $1.3B | 2024 |
| Mediar Therapeutics, Inc. | — | Biotechnology | Series C | $127.9M | $194.8M | 2022 |
| TScan Therapeutics, Inc. | — | Biotechnology | Series C | $123.3M | $3.3B | 2021 |
Nandita Shangari at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nandita Shangari on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Baran | 2 | 4 |
| Tim Shannon | 1 | 9 |
| Campbell Murray | 1 | 9 |
| Christoph Westphal | 1 | 8 |
| Robert Crane | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Ittai Harel | 1 | 6 |
| Meredith Fisher | 1 | 6 |
| Timothy Barberich | 1 | 6 |
| Steve Kraus | 1 | 6 |
| Laura Shawver | 1 | 6 |
| Peter Parker | 1 | 6 |
| Scott Phillips | 1 | 5 |
| Arjun Goyal | 1 | 5 |
| Andrew Hedin | 1 | 5 |
| Liam Ratcliffe | 1 | 4 |
| Brian Hubbard | 1 | 4 |
| Rebecca Luse | 1 | 3 |
| Allan Marchington | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.